Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 6/20 | 0.46 |
| ▸ | CA2 | P00918 | 6/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 2/20 | 0.36 |
| ▸ | CA6 | P23280 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29469805 | 1.00 | SRC (0.47) | SRCCA1CA2CA9CA12 | |
| SCHEMBL566044 | 0.90 | PNMT (0.47) | SRCCA1CA2CA9CA12 | |
| SCHEMBL525390 | 0.83 | SRC (0.50) | SRCCA1CA2CA9CA12 | |
| SCHEMBL7423714 | 0.83 | SRC (0.47) | SRCCA1CA2CA9CA12 | |
| Hydrochloric Acid SCHEMBL8986751 | 0.82 | SRC (0.49) | SRCCA1CA2CA9CA12 | |
| SCHEMBL7867515 | 0.81 | SRC (0.44) | SRCCA1CA2CA9CA12 | |
| SCHEMBL13696856 | 0.80 | F2 (0.44) | SRCCA1CA2CA9CA12 | |
| SCHEMBL16947604 | 0.77 | — | — | |
| SCHEMBL11327517 | 0.74 | PNMT (0.59) | CA1CA2CA9CA12PNMT | |
| SCHEMBL29800795 | 0.74 | SRC (0.39) | SRCCA1CA2CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279207-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-22 | — | — | US | disclosed |
| US-11299496-B2 | Ligands for alpha-7 nicotinic acetylcholine receptors and methods of treating neurological and inflammatory conditions | NORTHEASTERN UNIVERSITY (US) | 2022-04-12 | — | — | US | disclosed |
| US-10428017-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE S.Á.R.L. (LU) | 2019-10-01 | — | — | US | disclosed |
| US-20180244611-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE S.Á.R.L. (LU) | 2018-08-30 | — | — | US | disclosed |
| US-20180244640-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE S.Á.R.L. (LU) | 2018-08-30 | — | — | US | disclosed |
| WO-2018154493-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie S.à.r.l. (LU) | 2018-08-30 | — | — | WO | disclosed |
| WO-2018154519-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie S.à.r.l. (LU) | 2018-08-30 | — | — | WO | disclosed |
| CN-108191746-A | A kind of novel hydroxyl pyridine compounds and preparation method and application | 暨南大学 | 2018-06-22 | — | — | CN | disclosed |
| US-20170217984-A1 | Ligands for Alpha-7 Nicotinic Acetylcholine Receptors and Methods of Treating Neurological and Inflammatory Conditions | NORTHEASTERN UNIVERSITY | 2017-08-03 | — | — | US | disclosed |
| EP-3180086-A1 | LIGANDS FOR ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS AND METHODS OF TREATING NEUROLOGICAL AND INFLAMMATORY CONDITIONS | Northeastern University (US) | 2017-06-21 | — | — | EP | disclosed |
| WO-2016014847-A1 | LIGANDS FOR ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS AND METHODS OF TREATING NEUROLOGICAL AND INFLAMMATORY CONDITIONS | NORTHEASTERN UNIVERSITY (US) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428017-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, CLCN2, SCNN1G | SRC 3967/4885CA1 4864/4885CA2 1500/4885 |
| US-20180244611-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, CLCN2, SCNN1G | SRC 3967/4885CA1 4864/4885CA2 1500/4885 |
| US-20240279207-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | KAT6A, KAT6B, KAT2A | SRC 1713/4885CA1 1714/4885CA2 2865/4885 |
| US-20170217984-A1 | Ligands for Alpha-7 Nicotinic Acetylcholine Receptors and Methods of Treating Neurological and Inflammatory Conditions | CHRNA7, CHRNA10, CHRNA5 | SRC 2958/4885CA1 3072/4885CA2 3856/4885 |
| US-20180244640-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, CLCN2, SCNN1G | SRC 3967/4885CA1 4864/4885CA2 1500/4885 |
| US-11299496-B2 | Ligands for alpha-7 nicotinic acetylcholine receptors and methods of treating neurological and inflammatory conditions | CHRNA7, CHRNA10, CHRNA5 | SRC 2958/4885CA1 3072/4885CA2 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.